196 related articles for article (PubMed ID: 36947214)
61. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
62. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
63. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
64. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
65. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
66. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
[TBL] [Abstract][Full Text] [Related]
67. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
68. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
69. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
70. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
[TBL] [Abstract][Full Text] [Related]
71. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
72. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
73. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
[TBL] [Abstract][Full Text] [Related]
74. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
[TBL] [Abstract][Full Text] [Related]
75. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
76. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
[TBL] [Abstract][Full Text] [Related]
77. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
78. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.
Meguro A; Ozaki K; Sato K; Oh I; Fujiwara S; Hosonuma R; Sasazaki M; Kikuchi Y; Hirata Y; Yamamoto C; Uesawa M; Kobayashi H; Matsu H; Okabe H; Uehara E; Nishikawa A; Tatara R; Hatano K; Yamamoto C; Matsuyama T; Toshima M; Ueda M; Ohmine K; Suzuki T; Mori M; Nagai T; Muroi K; Ozawa K
Leuk Lymphoma; 2012 Jan; 53(1):43-9. PubMed ID: 21864040
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
Kawasaki N; Tomita M; Yamashita-Kashima Y; Yoshimura Y; Yoshiura S
Leuk Lymphoma; 2023 Dec; 64(12):1938-1948. PubMed ID: 37548343
[TBL] [Abstract][Full Text] [Related]
80. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT; Unger JM; Rimsza LM; LeBlanc M; Farnsworth B; Iannone M; Glenn MJ; Fisher RI; Miller TP
Blood; 2012 Aug; 120(6):1210-7. PubMed ID: 22734071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]